Aprocitentan in resistant hypertension with chronic kidney disease: balancing albuminuria reduction against early volume risk
Combining a new blood pressure drug with existing kidney-protective therapy may reduce fluid buildup while improving outcomes in resistant hypertension.
This review synthesizes Phase 3 PRECISION trial data to contextualize aprocitentan's BP-lowering and albuminuria benefits against its predictable front-loaded edema risk in patients with resistant hypertension and CKD. The authors propose combining aprocitentan with SGLT2 inhibitors to counterbalance the fluid retention and optimize the benefit-risk profile in this high-risk population.
What the study was
- Study design
- Narrative review
- Population
- Patients with resistant hypertension and chronic kidney disease
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of Human Hypertension
Why it surfaced
Clinically useful review of a recently approved drug (aprocitentan) in a high-risk comorbid population; SGLT2i combination hypothesis is novel. Limited by review design and lack of primary data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.